Anthera jumps 25% on blisibimod update, new endpoint
This article was originally published in Scrip
Executive Summary
Hayward, California-based Anthera Pharmaceuticals jumped 25% to close at $3.25 per share on 10 February after the company said an independent statistician recommended continuation of a Phase III lupus clinical trial for blisibimod following an interim analysis based on the trial's new primary endpoint.